Skip to main content
construction release_alert
Profile editing is temporarily unavailable from June 11-24, 2026 while manual profile data entry transitions to Elements. Learn More.
cancel

Gail A. Spiridigliozzi

Professor in Psychiatry and Behavioral Sciences
Psychiatry, Child & Family Mental Health & Community Psychiatry
Box 2906 Med Ctr, Durham, NC 27710
Exchange on Erwin, 2608 Erwin Road, Suite 300, Durham, NC 27705

Overview


Cholinergic therapy in children and adolescents with Down syndrome; premutation carriers of fragile X syndrome; cognitive development of children with infantile-onset Pompe disease who are being treated with enzyme replacement therapy.

Current Appointments & Affiliations


Professor in Psychiatry and Behavioral Sciences · 2022 - Present Psychiatry, Child & Family Mental Health & Community Psychiatry, Psychiatry & Behavioral Sciences
Professor in Pediatrics · 2022 - Present Pediatrics, Clinical Science Departments

Recent Publications


The Detection of Down Syndrome Arthritis in Clinical Practice: A Multicenter, International Pilot and Feasibility Study of a Down Syndrome-Specific Musculoskeletal Screening Tool.

Journal Article Am J Med Genet A · March 2026 Down syndrome (DS) is associated with an increased risk for an inflammatory arthritis termed Down syndrome-associated arthritis (DA). Clinical awareness of DA may prevent morbidity, but there is currently no consensus approach to screen for DA. A DS muscul ... Full text Link to item Cite

Longitudinal Characterization of Males With X-Linked Creatine Transporter Deficiency: Final Results of a Multiyear Observational Study.

Journal Article Pediatr Neurol · February 2026 BACKGROUND: The purpose of the Vigilan observational study (ClinicalTrials.gov, NCT02931682) was to prospectively assess the natural history and developmental course of creatine transporter deficiency (CTD). METHODS: Males with CTD aged 6 months to 65 year ... Full text Open Access Link to item Cite

Infantile-onset Pompe disease entering adulthood: Insights from 2 decades of enzyme replacement therapy experience.

Journal Article Genet Med · December 2025 PURPOSE: This study details the long-term clinical outcomes in adult participants with CRIM-positive infantile-onset Pompe disease treated with enzyme replacement therapy (ERT), initially reported in 2012 (n = 11). METHODS: Medical records were reviewed fo ... Full text Link to item Cite
View All Publications

Recent Grants


Understanding cognitive and neurological pathologies in infantile Pompe disease CNS

Clinical TrialInvestigator · Awarded by Genzyme Corporation · 2022 - 2030

Understanding cognitive and neurological pathologies in infantile Pompe disease

Clinical TrialInvestigator · Awarded by Genzyme Corporation · 2016 - 2018

What about adolescence? Living with genetic risk

ResearchCo Investigator · Awarded by National Institutes of Health · 2004 - 2007

View All Grants

Education


University of Kansas · 1988 Ph.D.